Bicara Therapeutics Touts Breakthrough Ficerafusp Data, Picks 1,500 mg Dose for FORTIFY-HNS Trial [Yahoo! Finance]
Bicara Therapeutics Inc. (BCAX)
Company Research
Source: Yahoo! Finance
enrollment by end-2026 and an interim analysis by mid-2027 with a potential early-2028 launch. Long-term ASCO 2025 data showed a 54% confirmed response rate (21% complete responses), median duration of response of 21.7 months and median overall survival 21 months in frontline HPV-negative head and neck cancer, supporting the FDA's Breakthrough Therapy Designation Management says it has “north of $400 million” to fund the pivotal study, is building commercial infrastructure (including hiring a CCO), and is expanding ficerafusp alfa into metastatic colorectal and other tumor cohorts with early CRC data expected in H2 2026. Interested in Bicara Therapeutics Inc.? Here are five stocks we like better. Bicara Therapeutics (NASDAQ:BCAX) used its presentation at the 44th Annual J.P. Morgan Healthcare Conference to outline its 2026 corporate outlook and highlight 2025 milestones centered on its lead clinical program, ficerafusp alfa, a bifunctional antibody designed to modulate the tum
Show less
Read more
Impact Snapshot
Event Time:
BCAX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BCAX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BCAX alerts
High impacting Bicara Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
BCAX
News
- Bicara Therapeutics (NASDAQ:BCAX) had its "buy" rating reaffirmed by analysts at BTIG Research.MarketBeat
- Bicara Therapeutics (NASDAQ:BCAX) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
- Bicara Therapeutics (NASDAQ:BCAX) had its "buy" rating reaffirmed by analysts at UBS Group AG.MarketBeat
- Bicara Therapeutics (NASDAQ:BCAX) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $30.00 price target on the stock.MarketBeat
- Bicara Therapeutics Announces Phase 3 Optimal Dose and Provides 2026 Corporate Outlook [Yahoo! Finance]Yahoo! Finance
BCAX
Earnings
- 11/10/25 - Miss
BCAX
Sec Filings
- 1/15/26 - Form 144
- 1/12/26 - Form 8-K
- 12/29/25 - Form 4
- BCAX's page on the SEC website